An investigation of the change in concentration time profile for the diuretic drug frusemide when administered orally and intravenously to individuals with oedema associated with pulmonary hypertension or compensated and decompensated congestive heart failure.

Flinders University0 个研究点目标入组 20 人开始时间: 2014年5月2日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•Adult males and females over the age of 18 years being treated for either acutely decompensated congestive heart failure or pulmonary hypertension by the appropriate physician specialists.
•Potential study participants will be enrolled into the respective arms of the study (acutely decompensated congestive heart failure or pulmonary hypertension) on the basis of clinician assessment of the following variables:
•Acutely decompensated congestive heart failure referred from the cardiology clinic:
•* Documented reduced ejection fraction (<45%).
•* Presence of at least one symptom (dyspnoea, orthopnoea, fatigue or oedema) and
•* Presence of at least one sign (rales, peripheral oedema, ascites, or pulmonary vascular congestion on chest radiography) of heart failure.
•Pulmonary hypertension referred from the pulmonary hypertension clinic and requiring frusemide to alleviate the congestion caused by right heart failure:
•* Documented elevation of pulmonary arterial pressures (either noninvasively by echocardiogram or invasively by right heart catheterization) >25 mmHg
•* Documented normal ejection fraction (>50%), and
•* Presence of at least one sign (lower limb oedema or ascites) of pulmonary hypertension.
•Compensated heart failure will be recognised by:
•* The assessment of the treating clinical team but should include: improvement of the principal symptom and improvement in signs of decompensated CHF

•Clinical symptoms: systolic blood pressure of less than 90mmHg, serum creatinine level >300microg/L, co-administered intravenous vasodilators or inotropic agents (other than digoxin). Documented ischaemic heart disease or systemic hypertension (pulmonary hypertension group only).

发起方